Navigation Links
Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
Date:5/28/2008

- Internationally Recognized Oncologists Will Offer Strategic Guidance on

Picoplatin Clinical Development -

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the appointment of four additional members to its Clinical Advisory Board to help guide the Company's expanding clinical development strategy for picoplatin. They include Howard A. Burris, III, M.D., of The Sarah Cannon Research Institute in Nashville; E. David Crawford, M.D., of the University of Colorado Comprehensive Cancer Center; Robert F. Ozols, M.D., Ph.D., of the Fox Chase Cancer Center in Philadelphia; and Everett E. Vokes, M.D., of the University of Chicago Pritzker School of Medicine.

These esteemed physicians will add to the already broad expertise of the Company's Clinical Advisory Board and bring an understanding of a wide variety of tumor types, including prostate, breast, ovarian, head and neck and lung cancers, to inform the development of picoplatin. Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to address multiple indications, combinations and formulations.

"These renowned physicians are experts in several different indications and will provide strategic input into our clinical development program for picoplatin, which is being developed as a platform product with broad applicability across multiple solid tumor types," said Robert De Jager, M.D., chief medical officer of Poniard.

The new Clinical Advisory Board members join existing members Paul J. Bunn, Jr., M.D., of the University of Colorado Comprehensive Cancer Center; Alan
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
2. Poniard Pharmaceuticals Announces Upcoming Conference Participation
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
6. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
7. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
8. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
9. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
10. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
11. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  Dr. Gerald Zon ... acid research, recently launched a new blog in conjunction ... ( zon.trilinkbiotech.com ), focuses on what,s trending in the ... industry thought leaders, discussions of research presented at conferences ... Dr. Zon (PhD Princeton University 1971) developed ...
(Date:5/20/2013)... With bed bugs' presence come problems in various terms. ... to be eliminated, one must make sure that the bed ... so to help bed bug sufferers get that done, it ... bugs without using harmful pesticides. In it, the company ... Bug Bully. , According to My Cleaning Products, contrary to ...
(Date:5/20/2013)... HILL, N.C. , May 20, 2013 /PRNewswire/ ... company focused on developing differentiated antibiotics to meet ... infections, today announced that it presented data at ... in Philadelphia demonstrating the ... levofloxacin in Cempra,s prior Phase 2 clinical trial ...
(Date:5/20/2013)... BOSTON , May 20, 2013 Rhythm ... clinical trial of RM-131, the company,s novel ghrelin agonist ... diabetic patients. The trial demonstrated that RM-131 significantly accelerates ... in type 1 diabetic patients with diabetic gastroparesis. The ... conference in Orlando and recently ...
Breaking Biology Technology:Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3
... Sept. 1 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus,Biotech Inc. ... manufacturer and marketer of a variety of cactus-based ... successfully completed the trial,production of cactus-based cigarettes and ... in 2009: (i) low nicotine and (ii) zero ...
... ANNAPOLIS, Md., Sept. 1 PharmAthene, Inc. (NYSE Amex: ... against biological and chemical threats, announced today that management will ... 2009. The Company is scheduled to present on Thursday, ... Salon (5th Floor) at the New York Palace Hotel, New ...
... FORT LAUDERDALE, Fla., Sept. 1 OmniComm Systems, Inc. (OTC ... data capture (EDC) solutions for clinical trials, and ... announced today that three additional clinical research organizations ... the CRO Preferred Program. The partnership allows CROs in the ...
Cached Biology Technology:China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes 2China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes 3OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 2OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 3
(Date:5/20/2013)... articles posted online ahead of print 9 ... of geoscience subdisciplines, including minerals exploration, archaeology, planetary ... include Siberia; the Sumatran subduction margin; the Monte ... and the Southeastern U.S. Atlantic Margin. Brief highlights ... tectonics;, 2. The clear fingerprint of ice ages ...
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... of New Jersey, and City University of New York ... that effectively clears organisms to be viewed under ... hydrate, which is one of the few high-quality clearing ... the Drug Enforcement Administration (DEA) due to its use ... are vital for viewing organisms under a microscope. Without ...
Breaking Biology News(10 mins):New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11Coffee consumption associated with reduced risk of autoimmune liver disease 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3
... more to fighting infection than just clearing the body of ... the host,s tissue caused, very frequently, by toxins produced by ... clears those pathogens. Indeed, it is the damage inflicted to ... the lethal outcome of some infectious diseases. , The ...
... the current issue of Science , researchers at Michigan ... light on how easy it can be for diseases to ... time how the virus called "Lambda" evolved to find a ... four mutations to accomplish. This virus infects bacteria, in particular ...
... -- (Jan. 26, 2012) -- Like a magician employing sleight ... player in diabetes, cancer and aging -- draws the eye ... subtle, more crucial action takes place somewhere else. Using ... Rice University and the University of California, San Diego (UCSD) ...
Cached Biology News:European Research Council supports search for regulators of tissue damage 2MSU researchers show how new viruses evolve, and in some cases, become deadly 2Rice, UCSD scientists probe form, function of mysterious protein 2Rice, UCSD scientists probe form, function of mysterious protein 3
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
6-keto Prostaglandin F1α EIA Antiserum 6-keto-PGF1alpha EIAs prostaglandins antisera enzyme immunoassays reagents 6-keto-PGF1.alpha....
...
Biology Products: